Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-15
$121.74-0.37%
Close 2026-09-15 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-15
Research Workspace
Put INCY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 27% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
Incyte's growth in total net sales and its advancements in the late-stage pipeline drive the investment thesis. Revenue grew 38% year over year, and the last quarter beat expectations significantly. It trades at 14× P/E versus a peer median of 22×, indicating that the price reflects less growth than forecasted. If Incyte cuts guidance after recently raising it, that could damage credibility. Peer multiples imply a price about 26% above where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-09-15. INCY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering INCY (as of Sep 2026).
Based on 14 Wall Street analysts offering 12-month price targets for INCY in the last 4 months.
Continue this research
Compare INCY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| INCY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put INCY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Pipeline updates support advancement of late-stage studies.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $121.74
The last 12 months of price, then the range of analyst 12-month targets from today’s $121.74.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
New data supports advancement of late-stage pipeline.
Advances: Increase total net sales and Hematology and Oncology sales
Sales growth aligns with management's goal for increased net sales.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Positive results support advancement of late-stage pipeline.
Advances: Increase Hematology and Oncology sales
Increased sales guidance supports growth in Hematology and Oncology.
Rating downgrade may impact investor sentiment and valuation.
Threatens: Increase Hematology and Oncology sales
Sales guidance miss impacts growth expectations.
Advances: Increase Hematology and Oncology sales
Better-than-expected sales support growth objectives.